|
Jul 24
|
Merck and GTRI to develop gene therapy for Parkinson’s disease
|
|
Jun 25
|
Merck KGaA abandons Phase III trial for $1.08bn head & neck cancer drug
|
|
Jun 25
|
Merck KGgA shares slide after failure of potential head and neck cancer drug
|
|
Jun 23
|
Merck KGaA's (ETR:MRK) Stock Has Fared Decently: Is the Market Following Strong Financials?
|
|
Jun 14
|
Here's What Could Help Merck KGaA (MKGAF) Maintain Its Recent Price Strength
|
|
May 13
|
Lula’s progress plan for Brazil: A year on
|
|
Dec 8
|
Merck Navigates Chip Geopolitics With ‘China For China’ Strategy
|
|
Dec 6
|
Merck KGaA: MS drug failure is a sour note for growth hopes
|
|
Dec 6
|
German Merck’s MS drug falls short in pair of Phase 3 tests
|
|
Dec 6
|
Merck KGaA Plunges as Multiple Sclerosis Drug Fails in Trial
|
|
Dec 6
|
Merck MS Drug Fails to Meet Target of Late-Stage Trials
|
|
Dec 5
|
UPDATE 3-Merck KGaA suffers major blow as MS drug fails in late-stage trials
|
|
Nov 27
|
Merck KGaA's (ETR:MRK) Intrinsic Value Is Potentially 85% Above Its Share Price
|
|
Oct 20
|
Health Care Roundup: Market Talk
|
|
Oct 19
|
Merck KGaA Sees Return to Organic Sales Growth Next Year
|
|
Oct 19
|
Merck KGaA raises prospect of return to sales growth next year
|
|
Oct 19
|
Merck KGaA says MS drug has blockbuster potential; key data expected in December
|
|
May 2
|
Will Weakness in Merck KGaA's (ETR:MRK) Stock Prove Temporary Given Strong Fundamentals?
|
|
Apr 28
|
Profound Medical (PROF) Moves 9.4% Higher: Will This Strength Last?
|
|
Apr 27
|
Germany in Talks to Limit Export of Chip Chemicals to China
|